Gonorrhea - Drug Pipeline Landscape, 2022

Gonorrhea is a sexually transmitted infection (STI) caused by the bacterium Neisseria gonorrhoeae. Gonorrhea most often affects the urethra, r*ctum or throat. In females, gonorrhea can also infect the cervix. Symptoms of Gonorrhea infection in men include painful urination, pain or swelling in one t*sticle and in women include increased vaginal discharge, painful urination, vaginal bleeding between periods and abdominal or pelvic pain. Diagnosis of Gonorrhea can be done after analyzing a sample of cells. Samples can be collected by urine test or swab of affected area.

Treatment for Gonorrhea include one-time intramuscular injection of the antibiotic ceftriaxone. There are several clinical trials currently ongoing in gonorrhea drug development. The most promising trials are testing new antibiotics against gonorrhea bacteria. These new antibiotics are designed to be more effective against gonorrhea bacteria than existing antibiotics. Other ongoing trials are testing vaccine candidates against gonorrhea. These vaccines are designed to prevent gonorrhea infections by inducing an immune response against the bacteria.

Read more about Gonorrhea - Drug Pipeline Landscape here: https://www.globalinsightservices.com/reports/gonorrhea-drug-pipeline-landscape-2022/

Report Highlights
Global Insight Service's, Gonorrhea - Drug Pipeline Landscape, 2022 report provides an overview of the Gonorrhea pipeline drugs. This report covers detailed insights on Gonorrhea drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Gonorrhea pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

To remain 'ahead' of your competitors, request for a sample: https://www.globalinsightservices.com/request-sample/GIS31043/

Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Key Players:

- Alopexx Pharmaceuticals Inc
- Biolytics Pharma
- Debiopharm International SA.
- Entasis Therapeutics
- Evofem Inc
- GlaxoSmithKline
- Microbiotix Inc

Get a Customized Scope to Match Your Need Ask an Expert: https://www.globalinsightservices.com/request-customization/GIS31043/

Contact Us:

Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

This release was published on openPR.